tradingkey.logo

TELA Bio Inc

TELA
查看詳細走勢圖
1.130USD
-0.010-0.88%
收盤 12/19, 16:00美東報價延遲15分鐘
45.59M總市值
虧損本益比TTM

TELA Bio Inc

1.130
-0.010-0.88%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-0.88%

5天

-1.74%

1月

+6.60%

6月

-31.52%

今年開始到現在

-62.58%

1年

-60.35%

查看詳細走勢圖

TradingKey TELA Bio Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

TELA Bio Inc當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名98/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價3.45。中期看,股價處於下降通道。近一個月,市場表現一般,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

TELA Bio Inc評分

相關信息

行業排名
98 / 208
全市場排名
228 / 4582
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 5 分析師
買入
評級
3.450
目標均價
+205.31%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

TELA Bio Inc亮點

亮點風險
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
業績高增長
公司營業收入穩步增長,連續3年增長67.32%
業績增長期
公司處於發展階段,最新年度總收入69.30M美元
估值高估
公司最新PE估值-1.38,處於3年歷史高位
機構減倉
最新機構持股28.74M股,環比減少25.58%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉1.80M股

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

TELA Bio Inc簡介

TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
公司代碼TELA
公司TELA Bio Inc
CEOKoblish (Antony)
網址https://www.telabio.com/

常見問題

TELA Bio Inc(TELA)的當前股價是多少?

TELA Bio Inc(TELA)的當前股價是 1.130。

TELA Bio Inc 的股票代碼是什麼?

TELA Bio Inc的股票代碼是TELA。

TELA Bio Inc股票的52週最高點是多少?

TELA Bio Inc股票的52週最高點是3.099。

TELA Bio Inc股票的52週最低點是多少?

TELA Bio Inc股票的52週最低點是0.865。

TELA Bio Inc的市值是多少?

TELA Bio Inc的市值是45.59M。

TELA Bio Inc的淨利潤是多少?

TELA Bio Inc的淨利潤為-37.84M。

現在TELA Bio Inc(TELA)的股票是買入、持有還是賣出?

根據分析師評級,TELA Bio Inc(TELA)的總體評級為買入,目標價格為3.450。

TELA Bio Inc(TELA)股票的每股收益(EPS TTM)是多少

TELA Bio Inc(TELA)股票的每股收益(EPS TTM)是-0.822。
KeyAI